Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octreotide hydrochloride
- Development stage
- Approved
- Lead developer
- Camurus
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Octreotide hydrochloride (specifically the CAM2029 formulation) is a long-acting subcutaneous depot of the somatostatin analog octreotide, developed by Camurus using its proprietary FluidCrystal injection depot technology. Designed for the treatment of acromegaly, neuroendocrine tumors, and polycystic liver disease, the FluidCrystal technology allows for a small-volume injection that transforms into a liquid crystalline gel upon contact with tissue fluids, providing sustained release of the drug over several weeks. Octreotide acts as a potent agonist at somatostatin receptors, primarily SSTR2 and SSTR5, which inhibits the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), as well as various gastroenteropancreatic hormones. This formulation aims to provide improved convenience and efficacy compared to existing monthly somatostatin analog injections.
- Brand names
- CAM2029CAM-2029CAM 2029
- Other names
- octreotide hydrochlorideOctreotide FluidCrystal
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on octreotide hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octreotide hydrochloride.